New combo aims to outsmart stubborn colorectal cancer
NCT ID NCT05504252
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether combining the immunotherapy nivolumab (Opdivo) with the chemotherapy oxaliplatin can help control or shrink metastatic colorectal cancer that is mismatch repair proficient (pMMR) or microsatellite stable (MSS)—types that usually don't respond well to immunotherapy alone. The study includes 80 adults with measurable tumors who haven't had prior chemotherapy for their advanced disease. Researchers hope the oxaliplatin will make the tumors more sensitive to nivolumab, potentially leading to longer-lasting disease control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nivolumab (Opdivo) and oxaliplatin (with 5-fluorouracil and folinic acid)
- What this could lead to
- If successful, this combination could offer a new way to control or shrink metastatic colorectal cancer that is hard to treat with standard therapies.
- What could go wrong
- This is a small, early-phase trial (80 people) with no results yet. The approach may not work for all patients, and side effects from the drugs could be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Akershus University Hospital
Lørenskog, Akershus, 1478, Norway
-
Oslo University Hospital
Oslo, Akershus, 0424, Norway
-
St Olavs Hospital
Trondheim, Trøndelag, 7006, Norway
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a new immunotherapy combo shrink Hard-to-Treat tumors?
- Breath of life: new test could sniff out gut cancers before they spread
- Gut instinct: listening to bowel sounds may reveal hidden clues about surgical recovery
- Triple therapy aims to wipe out colorectal cancer before surgery
- DNA 'Crystal Ball' may spot return of colorectal cancer